Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q1 2024 Earnings Presentation
22 slides from Marinomed Biotech's earnings presentation, May 22, 2024
Slide 1: Investor presentation Q1 2024
Investor presentation Q1 2024 Andreas Grassauer, CEO Pascal Schmidt, CFO Korneuburg, May 22nd, 2024
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda • Highlights year-to-date 2024 Andreas Grassauer, CEO • Financials Q1 2024 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed
Slide 4: Highlights year-to-date 2024
Highlights year-to-date 2024 Steady steps towards commercialization of our assets EIB agreement Carragelose Launch Solv4U 18 months deferral new distribution second long-term of allergen-blocker in of repayments to EIB partners for Gulf partnership with Austria and virus- and real estate region and
Slide 5: Agenda
Agenda • Highlights year-to-date 2024 Andreas Grassauer, CEO • Financials Q1 2024 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed
Slide 6: Revenue in line with post-pandemic market
Revenue in line with post-pandemic market High customer stock-levels lead to slow order intake Y-o-Y comparison of quarterly revenues (m€) Comments 4.2 Historical numbers 3.3 • Revenues declined to €0.7m (Q1/2023: €3.3m) 2.5 2.2 1.9 1.9 2.0 • Revenues largely related to Carragelose product portfolio
Slide 7: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) Revenues back on pre-pandemic level – cost-cutting program – stable result 1 Q1 2024 Q1 2023 €m Q1 2024 Q1 2023 Sale of goods 0.6 3.2 Revenues 1 0.7 3.3 Cost of goods sold -0.4 -2.1 Margin 33.0% 32.7% Other income 0.0 0.1 Materials expenses -0.4 -2.2 2 Q1 2024 Q1 2
Slide 8: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m Q1 2024 FY 2023 •1 Includes fully recognized headquarter, incl. land and Assets building (€5.3m), therein directly R&D related* (€0.4m) Intangible assets 1.5 1.5 2 Inventories €m Q1 2024 FY 2023 Property, plant and equipment 1 5.8 5.9 Goods for sale 0
Slide 9: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m Q1 2024 FY 2023 •1 Primarily related to EIB loan (€13.7m) and ERP/aws and Equity and liabilities NÖBEG real estate refinancing (€4.9m) Share capital 1.5 1.5 Majority of accrued interest payable at maturity of loans. Capital reserves 45
Slide 10: Stabilized cash situation
Stabilized cash situation Low cash drain due to Carragelose revenues and inflows from convertible bond program • Ended December 2022 with €8.2m in cash (as a result of the €6.0m EIB tranche 3 draw down) • Raised +€0.7m through convertible note funding program • Earned +€4.1m net cash through profita
Slide 11: Deferral of EIB repayments by 18 months
Deferral of EIB repayments by 18 months Real estate lenders also agreed to suspension Tranche I Tranche II Tranche III EUR 4 million EUR 5 million EUR 4.7 million Outstanding nominal Outstanding nominal Outstanding nominal October 2024 → April 2026 December 2025 → June 2027 December 2025 - August 20
Slide 12: Agenda
Agenda • Highlights year-to-date 2024 Andreas Grassauer, CEO • Financials Q1 2024 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed
Slide 13: Technologies & Therapeutic Areas
Technologies & Therapeutic Areas Universal blocking of viruses and allergens as well as Solubilization of poorly water-soluble compounds and moistening of mucosal tissues improving local onset of action Cough & cold Allergy Eye drops Budesolv Tacrosolv Solv4U portfolio* nasal spray* Dry, irritated A
Slide 14: Pipeline
Pipeline Including late-stage projects with low risk and meaningful upside potential Pharmaceutical Products Therapeutic Product Status Pre-clinical Phase I Phase II Phase III Filing Area Indication MAM-1004-1/Budesolv Filing in Treatment of severe allergic rhinitis preparation IMMUNOLOGY MAM-1003-1
Slide 15: Carragelose
Carragelose Universal blocking of viruses and allergens as well as moistening of mucosal tissues Recent developments & next steps • P&G: waiting for feedback on market authorization; preparation of possible launch in the upcoming season • New distribution partnerships for Gulf region Without Carrage
Slide 16: Marinosolv
Marinosolv Solubilization of poorly water-soluble compounds - improving local onset of action Recent developments & next steps • MAM-1004-1/Budesolv • Innovation in formulation & primary packaging → improved stability • BD process gaining momentum Aqueous formulation of hardly Marinosolv formulation
Slide 17: Agenda
Agenda • Highlights year-to-date 2024 Andreas Grassauer, CEO • Financials Q1 2024 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed
Slide 18: Summary project status (May 2024)
Summary project status (May 2024) Project Status/next steps MAM-1001-4 nasal spray Launched in Austria; drive BD-process for further partnerships Immunology MAM-1001-3 eye drops Complete clinical study in Spain and launch in 2024; drive BD-process MAM-1004-1/Budesolv Additional partnerships in 2024;
Slide 19: Translating innovation into top-line growth
Translating innovation into top-line growth Biotech business model with high upside potential Maximize Conclude Support Luoxin First Expand Solv4U value of further license towards next partnership for technology Carragelose agreements milestone Tacrosolv partnerships business for Budesolv Focus on g
Slide 20: Agenda
Agenda • Highlights year-to-date 2024 Andreas Grassauer, CEO • Financials Q1 2024 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact © Marinomed
Slide 21: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2024 Record Date for participation June 10, 2024 at the Annual General Meeting June 20, 2024 7th Annual General Meeting August 20, 2024 Publication of the Results H1 2024 November 21, 2024 Publication of the Results Q1-3 2024 Upcoming Events Lucia Z
Slide 22: www.marinomed.com
www.marinomed.com 0) Marinomed